阿尔茨海默病的分类:应用转移学习深度Q网络方法
Huibin Ma1,2, Yadan Wang1,2, Zeqi Hao3
1School of Information and Electronics Technology, Jiamusi University, Jiamusi, China.
The European journal of neuroscience
|January 29, 2024
概括
这项研究表明,使用深度Q网络 (DQN) 的转移学习可以有效地使用脑成像数据将阿尔茨海默病 (AD) 患者与健康个体区分开来. 这种方法实现了高精度,为早期AD诊断提供了有前途的工具.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 早期诊断阿尔茨海默病 (AD) 对于减缓疾病进展至关重要.
- 目前的诊断方法需要改进,以便及时有效地进行干预.
- 休息状态功能磁共振成像 (rs-fMRI) 提供了对大脑活动的见解.
研究的目的:
- 为了研究深度Q网络 (DQN) 转移学习方法对AD诊断的有效性.
- 利用rs-fMRI的局部大脑活动指标作为分类的特征.
- 评估该方法在区分AD患者与健康对照 (HC) 中的潜力.
主要方法:
- 利用了来自1310名受试者的rs-fMRI数据 (可靠性和可重复性联盟 - CoRR) 和50名受试者 (阿尔茨海默病神经成像倡议 - ADNI).
- 提取的局部大脑活动特征:低频波动的幅度 (ALFF),分数ALFF (fALFF) 和百分比波动的幅度 (PerAF) 使用Power 264图谱.
- 采用DQN分类器,在CoRR数据 (源域) 上进行预训练,并转移到ADNI数据 (目标域) 中,以分类AD与HC.
主要成果:
- 转移学习DQN模型的分类准确率达到86.66% (p < 0.01).
- 该模型显示回忆率为83.33%,在区分AD和HC时的精度为83.33%.
- 变换测试证实了分类性能的统计学意义.
结论:
- 使用DQN转移学习是区分AD患者与健康个体的可行和有效方法.
- 来自rs-fMRI的局部大脑活动指标具有临床AD诊断的重大潜力.
- 这种方法为改善阿尔茨海默病的早期检测和管理提供了一个有希望的途径.
更多相关视频
09:34A Virtual Machine Platform for Non-Computer Professionals for Using Deep Learning to Classify Biological Sequences of Metagenomic Data
Published on: September 25, 2021
4.0K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
